The long-lasting effect of ferumoxytol on abdominal magnetic resonance imaging

Journal of Computer Assisted Tomography

Volumn 38, Issue 4, 2014, Pages 571-573

  Harman, Aaron ^a   Chang, Kevin J ^a   Dupuy, Damian ^a   Rintels, Peter ^b  

^a BROWN UNIVERSITY   (United States)

^b Hematology and Oncology Associates of RI Inc ^*  (United States)

Author keywords

ferumoxytol; magnetic resonance imaging (MRI); mimic hemosiderosis; ultrasmall superparamagnetic iron oxide nanoparticles

Indexed keywords

DRUG DELIVERY; IRON OXIDES; METAL NANOPARTICLES; NANOMAGNETICS; RESONANCE; SUPERPARAMAGNETISM;

FERUMOXYTOL; FOOD AND DRUG ADMINISTRATION; IRON DEFICIENCY; LONG LASTING; MAGNETIC RESONANCE IMAGING; MIMIC HEMOSIDEROSIS; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES;

MAGNETIC RESONANCE IMAGING;

FERUMOXYTOL; GADOBUTROL; IRON;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG EFFECT; EPIGASTRIC PAIN; FEMALE; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON STORAGE; IRON THERAPY; LIVER FUNCTION TEST; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL;

ADRENAL GLANDS; BONE MARROW; FALSE POSITIVE REACTIONS; FEMALE; FERROSOFERRIC OXIDE; HEMOSIDEROSIS; HUMANS; IRON; LIVER; LIVER FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PARENTERAL NUTRITION SOLUTIONS; SPLEEN;

EID: 84904740773     PISSN: 03638715     EISSN: 15323145     Source Type: Journal    
DOI: 10.1097/RCT.0000000000000086     Document Type: Article

References (10)

1. Lu M, Cohen MH, Fieves D, et al. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol. 2010;85:315-319.
2. Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agent for MR imaging. Radiology. 1990;175:489-493.
3. Tanabe M, Ito K, Shimizu A, et al. Hepatocellular lesions with increased iron uptake on superparamagnetic iron oxide-enhanced magnetic resonance imaging in cirrhosis or chronic hepatitis: comparison of four magnetic resonance sequences for lesion conspicuity. Magn Reson Imaging. 2009;27:801-806.
4. Harisinghani M, Ross RW, Guimaraes AR, et al. Utility of a new bolus-injectable nanoparticle for clinical cancer staging. Neoplasia. 2007;9:1160-1165.
5. Neuwelt EA, Hamilton BE, Varallyay CG, et al. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Kidney Int. 2009;75:465-474.
6. Hamilton BE, Nesbit GM, Dosa E, et al. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging. AJR Am J Roentgenol. 2011;197:981-988.
7. McCullough BJ, Kolokythas O, Maki JH, et al. Ferumoxytol in clinical practice: implications for MRI. J Magn Reson Imaging. 2013;37:1476-1479.
8. Schieda N. Parenteral ferumoxytol interaction with magnetic resonance imaging: a case report, review of the literature and advisory warning. Insights Imaging. 2013;4:509-512.
9. Gunn AJ, Seethamraju RT, Hedgire S, et al. Imaging behavior of the normal adrenal on ferumoxytol-enhanced MRI: preliminary findings. AJR Am J Roentgenol. 2013;201:117-121.
10. Rostoker G, Griuncelli M, Loridon C, et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: an MRI study. Am J Med. 2012;125:991-999.